Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus-Reference-Cited by-同舟云学术

Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus

Published:2021-03 Issue: Volume:Volume 14 Page:319-326
ISSN:1178-7066
Container-title:Pharmacogenomics and Personalized Medicine
language:en
Short-container-title:PGPM

Author:

Pasternak Amy L^ORCID,Marshall Vincent D^ORCID,Gersch Christina L,Rae James M,Englesbe Michael,Park Jeong M^ORCID

Publisher

Informa UK Limited

Subject

Pharmacology,Molecular Medicine

Reference27 articles.

1. OPTN/SRTR 2018 Annual Data Report: Heart

2. OPTN / SRTR 2018 Annual Data Report: Kidney

3. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report

4. A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation

5. Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of CYP3A5 genotype-guided tacrolimus dosing in solid organ transplantation using real-world data;The Pharmacogenomics Journal;2024-05-15

2. Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients;Clinical and Translational Science;2023-06-26

3. Predictive Capacity of Population Pharmacokinetic Models for the Tacrolimus Dose Requirements of Pediatric Solid Organ Transplant Recipients;Therapeutic Drug Monitoring;2023-02

4. Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers;Clinical Transplantation;2023-01-11

5. Impact of Pharmacogenetics on Intravenous Tacrolimus Exposure and Conversions to Oral Therapy;Transplantation and Cellular Therapy;2022-01